Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: Exp Neurol. 2014 Mar 14;255:145–153. doi: 10.1016/j.expneurol.2014.03.004

Figure 3. hIgG does not affect NMO-IgG binding to AQP4.

Figure 3

A. Experimental protocol to quantify NMO-IgGc binding to AQP4 in CHO-AQP4 cells. Cells were incubated with NMO-IgGc and 40 mg/mL hIgG or BSA for 1 h at 23 °C. Cells were then washed, fixed and permeabilized. Bound NMO-IgGc was labeled with a red fluorescent secondary antibody and AQP4 with a C-terminus primary antibody and green fluorescent secondary antibody. B. Fluorescence micrographs showing bound NMO-IgGc (red) to AQP4 (green) in CHO-AQP4 cells after 1-h incubation with 20 μg/mL NMO-IgGc and 40 mg/mL hIgG or BSA. (right) NMO-IgGc binding quantified as red to green fluorescence ratio at 2.5 and 20 μg/mL NMO-IgGc and 40 mg/mL BSA or hIgG (mean ± S.E., n=5). C. Fluorescence micrographs showing bound NMO-IgGserum (red) and AQP4 (green) in CHO-AQP4 cells after 1-h incubation with 100 μg/mL NMO-IgGserum and 40 mg/mL BSA or rat IgG. (right) NMO-IgGserum binding quantified as in B (mean ± S.E., n=5).